retrovirus New Ano logo facebook_logo 1 twitter-logo retrovirus logo

Insert body text here...

Dr. Walter H. Gunzburg


Dr. Gunzburg is co-founder and Executive Chairman of the SG Austria Group, including Austrianova Singapore Pte Ltd, a life sciences company based at the Biopolis in Singapore. He has also been Professor of Virology at the University of Veterinary Medicine, Vienna in Austria since 1997. Previously he was Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development at the University of Vienna from 2003-2010, Chief Scientific Advisor to Austrianova group from 2001-2008 and Chief Scientific Advisor to Bavarian Nordic in Germany from 1994-2001. Walter has more than 20 years’ experience in virology, and over forteeen years’ experience in the business of cell therapy and bioencapsulation. As such he has published close to 100 peer reviewed scientific publications and book chapters in the field and is inventor of 17 patents and patent applications.

Advisory Board

Brian Salmons whg2

Dr. Brian Salmons, Director


Dr Salmons is co-founder, President and CEO of the SG Austria Group, including Austrianova Singapore Pte Ltd, a life sciences company based at the Biopolis in Singapore. He was Scientific Director with Bavarian Nordic in Germany ( from 1994-1999 where he was involved in taking the company to IPO in 1998. In 2000 he became CEO of start-up Austrian-Nordic Biotherapeutics AG and was directly responsible for Phase I/II clinical trial of an encapsulated cell therapeutic for pancreatic cancer. Between 2001 and 2008 he founded and managed the scientific direction of Austrianova Biotechnology GmbH and Austrianova Biomanufacturing AG in Vienna, Austria. March 2007 he was appointed Managing Director of the daughter company Austrianova Singapore Pte Ltd in Singapore. In June 2008, after an MBO, he stepped down from the European companies and became owner, President and CEO of SG Austria in Singapore. Brian has published over 80 peer reviewed scientific publications and book chapters in the field of molecular biology, cell therapy and virology and is inventor of 15 patents and patent applications.

Alex Matter Peter Wulff picture

Peter Wulff, Chairman


Since receiving his Master of Science in Organic Chemistry in 1980, Mr Wulff has gained 34 years experience in the biotech and pharma industry, especially vaccines, neuroscience and patents. Peter joined A/S Ferrosan in 1981 and became the Head of Patent Department. In 1992, he became a European Patent Attorney. In 1989, he was a co-founder of NeuroSearch A/S May 1989, a Danish corporation listed on the Copenhagen Stock Exchange developing drugs acting on the central nervous system. Peter was the Director of Patents and Licensing and Corporate Management member of NeuroSearch A/S until 1997. Peter then moved to become (1994 - 2007) President & CEO of Bavarian Nordic A/S, a Danish corporation in vaccines listed on the Copenhagen Stock Exchange. Peter co-founded Sentinext Therapeutics Sdn Bhd in 2008 and was the CEO until 2013. He is currently an Independent Consultant to the Biotech industry and the Chairman of Skau Vaccines Aps and a Board member of InProTher Aps. Mr. Wulff also sits on the Advisory Board of the Veterinary Institute at the Danish Technical University.

Dr. Alex Matter


A medical doctor by training, Alex followed his degree from the University of Basel with immunology and pathology research in Switzerland, Britain, France and USA before entering into the pharmaceutical industry. He has published more than 100 scientific articles plus several book chapters in the area of oncology and hematology. He is the recipient of the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award. He also was Associate Professor at the Medical School of the University of Basel for several decades and held fellowships at the Swiss National Science Foundation and the Swiss Academy for Medical Sciences. Alex is probably best known for his contribution to the development of Glivec/Gleevec, one of the world’s first tyrosine kinase inhibitor drugs against chronic myeloid leukemia (CML). Starting in the mid-eighties, he led a team of close to 200 scientists at Novartis to discover and optimize the lead compound and brought it all the way through its first clinical trial in 1998. Alex was the founding director for the Novartis Institute for Tropical Diseases in 2003 in Singapore. NITD also joined the Singapore Dengue consortium and the Global Alliance for TB Drug Development. He is a member of the Scientific Advisory Board of the Institute of Molecular and Cell Biology (IMCB) under the Singapore Agency for Science Technology and Research (A*STAR) since 2005, a member of the A*STAR Investigatorship Selection Panel in 2007 and was a member of the Experimental Therapeutics Centre (ETC) Project Review Committee in 2008. Alex is currently CEO of ETC (since 2009) and also CEO of the D3 platform (since 2012). Before coming to Singapore, Alex has held several positions of leadership such as Head of Cancer research at Hoffman-LaRoche, Head of Cancer and Virology Research at CIBA-GEIGY and more recently Global Head of Oncology Research, at Novartis Pharmaceuticals Corporation till 2003. Besides Glivec, his distinguished career with Novartis also includes heading drug discovery programs for anti-infectives and AIDS/HIV. Alex also co-founded the Esperanza Medicines Foundation, a non-profit organization that aims to develop affordable drugs for treatment and prevention of AIDS in developing countries.